UPC_APP_39459/2024

ANALYTE SENSOR

Prozessuale & UnteranträgeSonstige prozessualeDusseldorf LDGeneric application—Vergleich erfolgt: Während Hauptverfahren

Übersicht Entscheidungen Zitate Dokumente Zeitverlauf

Parteien

Kläger

Abbott Diabetes Care Inc.(Abbott Group)

Vertreter: Roland Küppers (Taylor Wessing); Alexander Rubusch (Taylor Wessing)

Beklagte

Sibio Technology Limited
Umedwings Netherlands B.V.

Vertreter: Thomas Gniadek (Simmons & Simmons)

Richter

ThomasPresiding Judge
ThomLegally Qualified Judge
BessaudLegally Qualified Judge
FulconisTechnically Qualified Judge

Patente

EP 2 393 417

CPC-Codes: A61B5/14865, A61B2560/0475, A61B5/72, A61B5/6898, H04L67/12, A61M2205/33, C12Q1/001, A61B2560/0487, A61B5/14503, A61B5/6849, A61M5/158, A61B5/0004…

Sektor: Biotechnology

Ausgang

Vergleich

Eingereicht: —

Erste Entscheidung: 3. Juli 2024

Sprache: —

Vergleich erfolgt: Während Hauptverfahren — settled commercially

Order by Düsseldorf Local Division (UPC_CFI_133/2024, 3 July 2024) confirming settlement between Abbott Diabetes Care Inc. and Sibio/Umedwings under R. 365.1(2) RoP in provisional measures proceedings over EP 2 393 417. A 20% reimbursement of court fees was ordered, the settlement having been reached at the oral hearing stage.